Enzolytics, Inc. (OTCMKTS:ENZC) Short Interest Update

Enzolytics, Inc. (OTCMKTS:ENZC) was the recipient of a large drop in short interest in March. As of March 13th, there was short interest totaling 209 shares, a drop of 88.8% from the February 26th total of 1,874 shares. Based on an average daily volume of 21,871,786 shares, the days-to-cover ratio is currently 0.0 days. Based on an average daily volume of 21,871,786 shares, the days-to-cover ratio is currently 0.0 days.

Enzolytics Stock Performance

Shares of ENZC stock remained flat at $0.00 during mid-day trading on Tuesday. The stock had a trading volume of 17,308,128 shares, compared to its average volume of 8,921,504. Enzolytics has a one year low of $0.00 and a one year high of $0.00.

Enzolytics Company Profile

Enzolytics, Inc is a clinical-stage biotechnology company focused on advancing immunotherapeutic treatments for infectious diseases. Its core platform employs proprietary peptide and monoclonal antibody technologies designed to target and neutralize viral pathogens. The company’s lead candidate, Investigator Therapeutic Vaccine-1 (ITV-1), is a 72-amino-acid peptide engineered to bind multiple HIV-1 strains and support immune response in affected individuals.

In addition to its HIV program, Enzolytics has leveraged its antibody discovery engine to develop broadly neutralizing monoclonal antibodies against coronaviruses, including SARS-CoV-2.